LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained
Complete. Here is the key summaryH.C. Wainwright reaffirmed a Buy rating on LB Pharmaceuticals with a $45 price target, citing clinical momentum for LB-102 and regulatory progress in the Phase 3 NOVA-2 schizophrenia trial. Piper Sandler also maintained a Buy rating with a higher $78 target. Analysts highlight the drug's robust trial design, strong cash position, and potential for accelerated approval as key drivers supporting the investment case.
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on LB Pharmaceuticals, Inc., with a price target of $45.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Ram Selvaraju has given his Buy rating due to a combination of factors tied to LB-102’s clinical and regulatory progress. He views the accelerated timeline for the pivotal Phase 3 NOVA-2 schizophrenia trial and the anticipated pre-NDA meeting with the FDA as materially increasing the visibility and potential speed to approval and commercialization, which supports his unchanged $45 price target.
He also highlights the robust design of NOVA-2 and the ongoing NOVA-3 long-term safety study as foundations for clinically meaningful and regulatory-grade data. In addition, he underscores LB Pharmaceuticals’ strong cash position and extended runway, which should carry the company through several key Phase 2 readouts in bipolar depression and adjunctive major depressive disorder, reinforcing confidence in LB-102’s broader therapeutic potential and the overall investment case.
In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $78.00 price target.